产品描述

来源:
Mouse
应用:
WB 1:500-1:2000, IHC-p 1:200-1:1000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
克隆:
Monoclonal [AFB1823]
特异性:
GFAP antibody detects endogenous levels of total GFAP.
RRID:
AB_2833847
引用格式: Affinity Biosciences Cat# BF0345, RRID:AB_2833847.
偶联:
Unconjugated.
纯化:
Affinity-chromatography.
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

wu:fb34h11; ALXDRD; cb345; etID36982.3; FLJ42474; FLJ45472; GFAP; GFAP_HUMAN; gfapl; Glial fibrillary acidic protein; Intermediate filament protein; wu:fk42c12; xx:af506734; zgc:110485;

抗原和靶标

免疫原:

Purified recombinant fragment of human GFAP expressed in E. Coli.

Uniprot:
基因/基因ID:
表达:
P14136 GFAP_HUMAN:

Expressed in cells lacking fibronectin.

描述:
This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant has been described, but its full length sequence has not been determined.
序列:
MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM

翻译修饰 - P14136 作为底物

Site PTM Type Enzyme
T7 Phosphorylation Q96GD4 (AURKB) , P17612 (PRKACA) , Q13464 (ROCK1)
S8 Phosphorylation P17612 (PRKACA)
R11 Methylation
R12 Methylation
S13 Phosphorylation Q13464 (ROCK1) , P17612 (PRKACA) , Q96GD4 (AURKB)
Y14 Phosphorylation
S17 Phosphorylation
S38 Phosphorylation Q96GD4 (AURKB) , Q13464 (ROCK1) , P17612 (PRKACA)
K95 Acetylation
Y116 Phosphorylation
T131 Phosphorylation
T150 Phosphorylation
K154 Acetylation
Y172 Phosphorylation
K189 Acetylation
K228 Acetylation
T240 Phosphorylation
Y242 Phosphorylation
K260 Acetylation
S305 Phosphorylation
Y324 Phosphorylation
K339 Acetylation
Y349 Phosphorylation

研究背景

功能:

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

翻译修饰:

Phosphorylated by PKN1.

细胞定位:

Cytoplasm.
Note: Associated with intermediate filaments.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Expressed in cells lacking fibronectin.

亚基结构:

Interacts with SYNM (By similarity). Isoform 3 interacts with PSEN1 (via N-terminus).

蛋白家族:

Belongs to the intermediate filament family.

研究领域

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

文献引用

1). Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020 (PubMed: 32182488) [IF=6.7]

Application: IF/ICC    Species: Mouse    Sample: BV2 and C6 cells

Fig. 4. Effects of compounds on GFAP and Iba-1 expression in the LPS-induced astrocytes (C6, treated with 10 mg/mL of LPS) and microglia (BV2, treated with 1 mg/mL of LPS). A. Representative fluorescence microscopy images of GFAP immunostaining (Magnification  20). B. Representative fluorescence microscopy images of Iba-1 immunostaining (Magnification  40). C. Histograms show relative changes of GFAP expressed as mean ± SD of the three independent experiments (n ¼ 3). Ctrl. ¼ Control, LPS ¼ Lipopolysaccharide (10 mg/mL); 3, 13, 16 ¼ treatments by compounds 3, 13, 16 (20 mM) along with LPS (10 mg/mL). D. Histograms show relative changes of Iba-1 expressed as mean ± SD of the three independent experiments (n ¼ 3). All the data were analyzed using Image Pro Plus and expressed as a percent of LPS group values (fluorescence intensity). (#) Significant difference (##p < 0.01, ###p < 0.001) vs. control and (*) significant difference (*p < 0.05 and **p < 0.01) vs. LPS.

2). Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates Detrusor Hyperactivity with Impaired Contractility via Transient Potential Vanilloid Channels: A Rat Model for Ovarian Hormone Deficiency. International journal of molecular sciences, 2024 (PubMed: 38732143) [IF=5.6]

Application: WB    Species: Rat    Sample:

Figure 4 LiESWT increased neuronal regeneration, synaptic transmission, and receptor response. The expressions of neuronal endogenous markers (NF, NeuN, and GFAP) and muscarinic receptor (M2 and M3), and purinergic receptor (P2X7) markers were assessed by immunostaining (A–H) and Western blots (I,J). Nuclear DNA was labeled with DAPI (blue). (A–D) The M2 immunostaining was markedly expressed in the UL and SL of the (A) sham group. On the contrary, there was less M2 staining expression in the thinner and defective urothelial mucosa in the UL (yellow arrows) of the (B) OVX group, but the immunostainings in the (C) OVX + SW4 group and the (D) OVX + SW8 group were enhanced. (E–H) Double-labeled analysis of M2 (red, upper panels) and NF (green, lower panels) was distributed in the ML of the (E) sham group. However, the double staining of the (G) OVX + SW4 group and the (H) OVX + SW8 group were widely expressed compared with the (F) OVX group. (I,J) Quantifications of the percentage of neurogenesis-related markers, muscarinic receptors, and purinergic receptors were evaluated by Western blotting. The expressions obviously decreased in the OVX group compared with the sham group. However, the expressions significantly increased in the OVX + SW4 group and OVX + SW8 group compared with the OVX group. Therefore, the LiESWT promoted bladder synaptic transmission, receptor response, and neurogenesis to ameliorate the bladder detrusor contractile response. Nuclear DNA was labeled with DAPI (blue). LiESWT, low-intensity extracorporeal shock wave therapy; OVX + SW4, OHD status for 12 months, followed by once weekly LiESWT for 4 weeks; OVX + SW8, OHD status for 12 months, followed by twice weekly LiESWT for 4 weeks; DAPI, 4′,6-diamidino-2-phenylindole; NF, neurofilament; NeuN, neuronal nuclear antigen and neuron; GFAP, glial fibrillary acidic protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UL, urothelial layer; SL, suburothelial layer. Data are expressed as the means ± SD for n = 8. * p < 0.05 and ** p < 0.01 versus the sham group; ## p < 0.01 versus the OVX group; †† p < 0.01 versus the OVX + SW4 group.

3). LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response. International Journal of Molecular Medicine, 2023 (PubMed: 37026522) [IF=5.4]

4). Carbenoxolone has the potential to ameliorate acute incision pain in rats. Molecular Medicine Reports, 2021 (PubMed: 34013377) [IF=3.4]

Application: IF/ICC    Species: rat    Sample:

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red)expression was analyzed using an immunofluorescence assay.Magnification, x200; scale bar, 10 µm. C,control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein

Application: IF/ICC    Species:    Sample:

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red) expression was analyzed using an immunofluorescence assay. Magnification, x200; scale bar, 10 µm. C, control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein.

5). Emodin inhibits HDAC6 mediated NLRP3 signaling and relieves chronic inflammatory pain in mice. Experimental and therapeutic medicine, 2024 (PubMed: 38144917) [IF=2.7]

Application: WB    Species: Mouse    Sample: spinal cord

Figure 2 Emodin reduces spinal cord inflammatory response by inhibiting spinal cord astrocyte activation. Representative (A) hematoxylin and eosin-stained images and (B) inflammation score analysis of the spinal dorsal horn in each group. Scale bar, 20 µm. Representative (C) immunofluorescence staining images of IL-1β and GFAP and (E) quantitative fluorescence intensity analysis (overall magnification, x400; scale bar, 20 µm). (D) Western blot analysis and (F) quantification of the relative grey value of IL-1β and GFAP. Data are presented as the mean ± SD (n=5). *P

6). Electroacupuncture prevents the development or establishment of chronic pain via IL-33/ST2 signaling in hyperalgesic priming model rats. Neuroscience letters, 2024 (PubMed: 38142925) [IF=2.5]

7). The effect of AQP4 on tau protein aggregation in neurodegeneration and persistent neuroinflammation after cerebral microinfarcts. Open medicine (Warsaw, Poland), 2023 (PubMed: 37873537) [IF=2.1]

Application: IF/ICC    Species: Mouse    Sample:

Figure 1 Effects of AQP4 on GFAP and p-tau aggregation. (a and b) Histology, qPCR, and Western blot assays verify adenovirus efficiency; (c and d) GFAP and AQP4 and p-tau aggregation (pSer202/pThr205, p-tau) and neuronal marker (NeuN) co-expression were evaluated by Immunofluorescence double staining. *p < 0.05 vs control. All experiments were repeated 3 times. Each group has 7 mice.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.